Day One Biopharmaceuticals, Inc. (DAWN)
NASDAQ: DAWN · IEX Real-Time Price · USD
17.57
-0.12 (-0.68%)
At close: May 2, 2024, 4:00 PM
18.02
+0.45 (2.58%)
Pre-market: May 3, 2024, 8:03 AM EDT
DAWN Employees
Day One Biopharmaceuticals had 155 employees on December 31, 2023. The number of employees increased by 34 or 28.10% compared to the previous year.
Employees
155
Change (1Y)
34
Growth (1Y)
28.10%
Revenue / Employee
n/a
Profits / Employee
-$1,218,819
Market Cap
1.54B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 155 | 34 | 28.10% |
Dec 31, 2022 | 121 | 66 | 120.00% |
Dec 31, 2021 | 55 | 35 | 175.00% |
Mar 31, 2020 | 20 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Tilray Brands | 1,600 |
Veracyte | 815 |
LeMaitre Vascular | 630 |
ADMA Biologics | 624 |
InMode | 581 |
Dynavax Technologies | 408 |
Ardelyx | 267 |
Kura Oncology | 142 |
DAWN News
- 9 days ago - Day One's OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor - GlobeNewsWire
- 2 months ago - Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress - GlobeNewsWire
- 4 months ago - Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 6 months ago - Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine - GlobeNewsWire
- 6 months ago - Day One Reports Third Quarter 2023 Financial Results and Corporate Progress - GlobeNewsWire
- 6 months ago - Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG) - GlobeNewsWire
- 8 months ago - Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG) - GlobeNewsWire
- 9 months ago - Day One Reports Second Quarter 2023 Financial Results and Corporate Progress - GlobeNewsWire